drugset / Trial / NCT01583738

Effect of V0251 in Acute Vertigo

NCT01583738 ↗

Phase 2 Completed 132 enrolled Pierre Fabre Laboratories
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Assessment of efficacy and tolerance of a new anti-dizziness drug in acute vertigo.

Timeline

Start
2012-04
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject V0251 Unknown — —

Indications

No indication recorded.